Crossmark

The role of budget impact in reimbursement decisions in The Netherlands: interviews with decision-makers and pharmaceutical industry representatives

Published Online: 2025-04-09

Published Print: 2025-11

Authors

Reckers-Droog, Vivian https://orcid.org/0000-0001-8722-3431
Enzing, Joost

Brouwer, Werner
Funding

Funding for this research was provided by:

Roche

AstraZeneca
License Information

Text and Data Mining valid from 2025-04-09

Version of Record valid from 2025-04-09
More Information

Article History

Received: 10 July 2024

Accepted: 19 February 2025

First Online: 9 April 2025

Declarations

:

: The Research Ethics Review Committee of the Erasmus School of Health Policy & Management assessed and waived ethical approval for this study (reference: ETH2122-0624).

: Dr. Reckers-Droog reports grants from Roche and AstraZeneca, during the conduct of the study. Dr. Enzing reports no conflicts of interest. Dr. Brouwer reports grants from Roche and AstraZeneca, during the conduct of the study. Dr. Brouwer reports being member of the Scientific Advisory Board (WAR) of the National Health Care Institute. No other conflicts of interest are reported.

Document is current